CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Onivyde Nanoliposomal Irinotecan Cancelled
Cyramza Ramucirumab Cancelled
Erbitux Cetuximab Cancelled
Atriance Nelarabine Cancelled
Admelog Insulin lispro Cancelled
TBD Rituximab Cancelled
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
TBD Bevacizumab Cancelled
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Twynsta Telmisartan / Amlodipine Hypertension Cancelled
Xeljanz tofacitinib Cancelled
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
Xolair Omalizumab Asthma, severe persistent Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Neupro Rotigotine Parkinson’s disease List with clinical criteria and/or conditions Complete
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from breast cancer List with clinical criteria and/or conditions Complete
Naglazyme Galsulfase (Drug Plan Submission) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) List with clinical criteria and/or conditions Complete
Jinarc Tolvaptan Autosomal dominant polycystic kidney disease Do not list Complete
Last Updated : July 27, 2024